Add-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir
Table 2
Comparison of pre- and on-treatment factors between the viral response and no viral response groups.
Factors
VR ()
No VR ()
Age (years) (range)
52 (36–62)
44 (30–65)
0.211
Sex (male/female)
10/2
6/5
0.193
Body weight (kg)
65.9 (53.0–91.0)
56.6 (45–110.5)
0.104
BMI (kg/m2)
23.9 (17.9–30.1)
21.2 (17.9–32.3)
0.151
Prior interferon therapy
2
5
0.193
History of HCC treatment
4
2
0.640
Genotype B/C
1/11
1/10
1.000
Duration of prior entecavir (days)
1831 (560–2275)
1316 (371–2410)
0.190
HBe Ag positive
4
4
1.000
HBV-DNA (log IU/mL)
2.1 (0–2.1)
2.1 (0–2.4)
0.740
HBs Ag (IU/mL)
1358 (112–5807)
1546 (778–19674)
0.651
Liver cirrhosis
7
4
0.414
IL28B (rs8099917) major
11
9
0.590
White blood cell (/mm3)
4765 (3260–9100)
5230 (2920–6630)
0.740
Hemoglobin (g/dL)
14.9 (14.0–15.8)
14.6 (12.0–16.5)
0.379
Platelets (×104/mm3)
18.8 (9.3–28.4)
17.1 (10.4–25.2)
0.487
AST (IU/L)
25 (14–34)
23 (14–31)
0.449
ALT (IU/L)
24 (16–47)
17 (10–32)
0.032
GTP (IU/L)
29 (13–81)
22 (11–82)
0.288
AFP (ng/mL)
2.2 (1.0–6.9)
2.7 (1.2–4.6)
0.651
Type IV collagen 7S (ng/mL)
3.8 (2.5–5.4)
3.5 (2.7–4.7)
0.833
Hyaluronic acid (ng/mL)
62 (10–266)
44 (26–94)
0.379
HBs Ag at week 4 (IU/mL)
1434 (101–5525)
1637 (694–21699)
0.651
Percentage reduction of HBs Ag at week 4
6 (−35–32)
−1 (−12–21)
0.880
HBs Ag at week 8 (IU/mL)
1159 (118–4286)
1544 (608–19397)
0.288
Percentage reduction of HBs Ag at week 8
22 (−5–51)
1 (−37–38)
0.091
HBs Ag at week 12 (IU/mL)
857 (57–4391)
1575 (591–23678)
0.134
Percentage reduction of HBs Ag at week 12
35 (−4–58)
9 (−29–41)
0.004
HBs Ag at week 16 (IU/mL)
966 (2–3703)
1329 (570–27476)
0.190
Percentage reduction of HBs Ag at week 16
32 (13–98)
14 (−40–36)
0.007
VR, viral response; HCC, hepatocellular carcinoma; HBe Ag, hepatitis B e antigen, HBs Ag, hepatitis B surface antigen; HBV, hepatitis B virus; IL, interleukin; ALT, alanine aminotransferase; GTP, -glutamyltransferase. Values are expressed as medians (range) or numbers of patients (percent).
